US20120190081A1 - Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same - Google Patents
Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same Download PDFInfo
- Publication number
- US20120190081A1 US20120190081A1 US13/278,102 US201113278102A US2012190081A1 US 20120190081 A1 US20120190081 A1 US 20120190081A1 US 201113278102 A US201113278102 A US 201113278102A US 2012190081 A1 US2012190081 A1 US 2012190081A1
- Authority
- US
- United States
- Prior art keywords
- cysteine
- serb
- opss
- ops
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01065—O-Phosphoserine sulfhydrylase (2.5.1.65)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03003—Phosphoserine phosphatase (3.1.3.3)
Definitions
- the present invention relates to a method for production of cysteine or its derivatives using O-phosphoserine as an intermediate and recombinant microorganism for use in production of O-phosphoserine.
- L-cysteine is an amino acid that plays an important role in sulfur metabolism of all living organisms. It is used in the biosynthesis of proteins, such as hair keratin, glutathione, biotin, methionine and other sulfur-containing metabolites as well as serving as a precursor of coenzyme A.
- proteins such as hair keratin, glutathione, biotin, methionine and other sulfur-containing metabolites as well as serving as a precursor of coenzyme A.
- cysteine is known to be closely associated with the biosynthesis of other amino acids including L-serine, L-glycine, and L-methionine.
- L-cysteine and its derivatives find applications in a variety of fields including the pharmaceutical industry (for treatment of bronchial diseases), the cosmetics industry (in hair shampoo, compositions for permanent waves), and the food industry (antioxidants, flavorant enhancers, dough aids, etc.).
- L-cysteine was once obtained industrially by acid hydrolysis of human hairs or animal feathers (Biotechnology of the Amino Acids Production edited by Ko Aida, p 217-223, 1986).
- cysteine from hairs or feathers ensure a yield of as low as 7 ⁇ 8%
- hydrochloric acid or sulfuric acid produces a lot of waste resulting in environmental pollution.
- extraction from hairs or feathers may induce the user to have a strong aversion thereto.
- L-cysteine Representative among the microbial production of L-cysteine is 1) the biological conversion of D,L-ATC using a microorganism (Ryu O H, Ju J Y and Shin C S, Process Biochem., 32:201-209, 1997). This conversion process is, however, difficult to apply industrially due to the low solubility of the precursor D,L-ATC. 2) Another method of L-cysteine production is direct fermentation using E. coli (Patent No. EP0885962B; Wada M and Takagi H, Appl. Microbiol. Biochem., 73:48-54, 2006).
- L-cysteine-exporting proteins are employed, but there have been no significant improvements in productivity.
- O-acetyl-serine acts as an intermediate precursor providing the carbon backbone of L-cysteine (Kredich N M and Tomkins G M, J. Biol. Chem., 241: 4955-4965, 1966).
- the enzyme O-acetylserine sulfhydrylase (OASS) using hydrogen sulfide as a sulfur donor, catalyses the conversion of O-acetylserine to cysteine.
- cystein may be produced using microorganisms accumulating OAS and OASS using various sulfur donors (U.S. Pat. No. 6,579,705).
- the cysteine biosynthesis pathway via OAS uses the two enzymes of serine acetyltransferase (CysE), which catalyzes the conversion of OAS from serine, and cysteine synthase (CysK), which catalyzes the conversion of OAS to cysteine.
- CysE serine acetyltransferase
- O-phosphoserine sulfhydrylase OPSS
- Aeropyrum pernix Aeropyrum pernix
- Mycobacterium tuberculosis and Trichomonas vaginalis that takes an O-phospho-L-serine (OPS)-specific pathway, rather than the OAS-specific pathway, to synthesize L-cysteine through intensive research
- OPS O-phospho-L-serine
- the method of the present invention in which O-phosphoserine is produced at high yield by a recombinant microorganism and is used for conversion into cysteine, as it is, is more friendly to the environment and ensures higher efficiency in the production of cysteine than do chemical synthesis methods.
- the cysteine and its derivatives produced by the fermentation and bioconversion of the present invention can be widely used in the production of animal and human foods and food additives.
- FIG. 1 is a schematic diagram showing the accumulation of O-phosphoserine by microbial fermentation and the enzymatic conversion of the accumulated O-phosphoserine into L-cysteine.
- FIG. 2 is a graph showing the activity of OPS sulfhydrylase according to temperatures.
- FIG. 3 is a set of graphs showing pH sensitivity of OPS sulfhydrylase.
- FIG. 4 is a photograph showing the expression level of Msm-T in a pET system and a pCL-Pcj1 system as analyzed by SDS PAGE.
- FIG. 5 is a graph showing the enzymatic activity of OPS sulfhydrylase to convert purified OPS fermentation broth into cysteine.
- FIG. 6 is a graph showing the enzymatic activity of OPS sulfhydrylase to convert OPS fermentation broth into cysteine.
- cyste conversion is intended to refer to the catalytic reaction of O-phosphoserine sulfhydrylase (OPSS) which results in the conversion of the substrate O-phosphoserine (OPS) into the product cysteine, that is, it refers to the catalytic reaction of converting OPS into cyteine.
- OPS O-phosphoserine sulfhydrylase
- cyste conversion rate refers to the percentage of the amount of the product cysteine to the amount of the starting material OPS. Under optimal reaction conditions, 1 mole of OPS is converted into 1 mole of cysteine. For example, if 100 moles of OPS is converted into 100 moles of cysteine, the cysteine conversion rate is 100%.
- the present invention provides a method for producing cysteine or a derivative thereof, comprising:
- step 1) culturing a recombinant microorganism in which the activity of endogeneous phosphoserine phosphatase (SerB) is reduced, to produce O-sphosphoserine (OPS); and 2) reacting the OPS of step 1) with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism expressing OPSS, to produce cysteine or a derivative thereof.
- SerB endogeneous phosphoserine phosphatase
- OPS O-sphosphoserine
- the SerB is a protein that has the activity of hydrolyzing OPS into L-serine.
- a microorganism which has reduced endogeneous SerB activity is characterized by the accumulation of OPS therein.
- the SerB is not limited to, may comprise any amino acid sequences, which exhibits SerB activity, and may have preferably the amino acid sequence of SEQ ID NO: 1 or 2.
- any amino acid sequence is used, which preferably has a homology of 90% or higher, more preferably 96% or higher, far more preferably 98% or higher, and most preferably 99% or higher with that of SEQ ID NO: 1 or 2.
- the reduced SerB activity means a decrease in SerB activity, compared to that of a prior-modified strain, and encompasses the disrupting of SerB.
- Various techniques for reduction of SerB activity are well known in the art. Illustrative examples include the deletion of a chromosomal serB, the introduction of mutation into the chromosomal serB to reduce endogenouse SerB activity, the introduction of mutation into a regulatory region for the serB to reduce endogenouse SerB activity, the substitution of the chromosomal serB with a gene mutated to reduce the endogenouse SerB activity, the introduction of mutation into a regulatory region for the serB to reduce endogenouse SerB activity, and the introduction of an antisense oligonucleotide complementary to a transcript of the serB to inhibit the translation of the mRNA, but methods for reducing the SerB activity are not limited to these. These techniques may be applied to the reducing the activity of other enzymes in the present invention.
- Glycine may be provided in the form of purified glycine, a glycine-containing yeast extract, or tryptone. Glycine is contained at a concentration of from 0.1 to 10 g/L, and preferably at a concentration of from 0.5 to 3 g/L.
- serine it may be provided in the form of purified serine, a serine-containing yeast extract or tryptone. Its concentration in the culture medium ranges from 0.1 to 5 g/L, and preferably from 0.1 to 1 g/L.
- mutant Corynebacterium glutamicum or E. coli in which the activity of endogeneous SerB was disrupted was found to produce a higher amount of OPS, compared to the wild-type (see Tables 2, 3, 4 and 5).
- the recombinant microorganism of the present invention refers to any microorganism which is modified to reduce SerB activity, thus producing OPS at an elevated level. If this condition is satisfied, any microorganism, whether prokaryotic or eukaryotic, falls within the scope of the present invention. Representative among them are enterobacteria or coryneform bacteria. Examples of the microorganisms useful in the present invention include Escherichia sp., Erwinia sp., Serratia sp., Providencia sp., Corynebacterium sp., and Brevibacterium sp. Preferable are Escherichia sp. and Corynebacterium sp, with more preference given for Escherichia sp. and with the highest preference being for E. coli.
- the strain capable of producing OPS was named E. coli CA07-0012, and deposited with the Korean Culture Center of Microorganisms, located at 361-221, Hongje 1, Seodaemun, Seoul, Korea, on Oct. 12, 2011 under accession number KCCM11212P.
- the term “culturing” is intended to mean growing microorganisms under artificially controlled conditions.
- a culturing procedure may be conducted using a suitable medium and culturing conditions well known in the art. Those skilled in the art can readily control the culturing procedure to correspond to the strains employed. For example, it may be performed in a batch type, in a continuous type, or in a fed-batch type, but is not limited thereto.
- the culture medium contains a carbon source.
- the carbon source include saccharides and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch and cellulose, oils and fats such as soybean oil, sunflower oil, castor oil and coconut oil, fatty acis such as palmitic acid, stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid.
- These carbon sources may be present solely or in combination in the culture medium.
- an organic material such as peptone, yeast extract, meat juice, malt extract, corn steep liquor, soybean, and wheat protein, or an inorganic nitrogen compound such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate may be contained in the culture medium.
- nitrogen sources may be used solely or in combination.
- the medium may contain potassium dihydrogen phosphate, potassium phosphate, or corresponding sodium salts as a phosphorous source.
- the medium may contain metallic salts such as magnesium sulfate or iron sulfate.
- the culture medium may also contain amino acids, vitamins and suitable precursors. The nutrients may be added in a batch manner or a continuous manner to the medium.
- a compound such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid may be added in a suitable manner to the culture medium during culturing to adjust the pH of the culture.
- an anti-foaming agent such as fatty acid polyglycol ester is used to suppress the formation of foam.
- oxygen or oxygen-containing gas can be injected into the culture medium.
- nitrogen, hydrogen, or carbon dioxide is provided without aeration.
- the culture medium may be typically maintained at a temperature of from 27° C. to 37° C. and preferably at a temperature of from 30° C. to 35° C. As for the culture period, it may be maintained until the product of interest is obtained in a desired amount, and preferably it ranges from 10 to 100 hours.
- a suitable method well known in the art may be selected depending on the type of culture, be it a batch, continuous or fed-batch culture.
- step 2) addresses the reaction of the OPS of step 1) with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism expressing OPSS, to induce the conversion of O-phosphoserine into cysteine or its derivatives.
- OPS O-phosphoserine sulfhydrylase
- the sulfide may be provided in a liquid or gas form as well as in a solid form typically used in the art, because of the difference in pH, pressure and/or solubility. So long as it may be converted to a thiol group (SH), any sulfur compound such as sulfide (S 2 ⁇ ) or thiosulfate (S 2 O 3 2 ⁇ ) may be used in the present invention.
- S 2 ⁇ thiosulfate
- Na 2 S, NaSH, H 2 S, (NH 4 ) 2 S, NaSH and Na 2 S 2 O 3 all of which can provide a thiol group for OPS, may be used.
- one thiol group is supplied to one OPS molecule to afford one molecule of cysteine or a derivative thereof.
- a sulfide may be preferably added at a molar concentration 0.1 to 3 times and more preferably 1 to 2 times as high as that of OPS used.
- a thiol group-providing sulfide and OPS are most preferably used at a molar ratio of 1:1.
- Na 2 S was used as the source of sulfur.
- Na 2 S was added at a molar concentration 1 to 3 times as high as that of OPS used in the conversion reaction.
- it is fed at a molar concentration twice as high as that of OPS to effectively convert OPS into cysteine (Table 15).
- OPS O-phosphoserine sulfhydrylase
- mutant refers to a culture or an individual that shows an inheritable or non-heritable alteration in phenotype.
- OPSS OPSS enzyme which is genetically altered such that its activity can be effectively enhanced, compared to the wild-type.
- the OPSS mutant can be constructed by deleting, substituting or adding a part of a nucleotide sequence encoding OPSS.
- an OPSS enzyme with enhanced activity was prepared by deleting five C-terminal amino acid residues of the OPSS enzyme of Mycobacterium smegmatis .
- the mutant enzymes have the amino acid sequences of SEQ ID NO: 4 and 5.
- the OPSS mutant can be obtained in E. coli , widely used for enzyme expression, using gene synthesis techniques based on codon optimization by which enzymes of interest can be obtained in high yield. Alternatively, screening methods of useful enzyme resources based on the bioinformatics of massive amounts of genetic information about microorganisms may be used to obtain the OPSS mutant.
- OPSS enzymes that utilize OPS as a substrate to synthesize cysteine were selected from various microbes by screening the homology of amino acid sequences. In this regard, cell pellets obtained using a medium and culture conditions that were suitable in the art were lyzed, followed by the purification of the supernatant containing the enzyme to afford the OPSS enzyme (Table 7).
- a high-yield expression system was developed for obtaining the OPSS enzyme economically.
- a pET vector employing a T7 promoter is well known in the art.
- the present inventors developed an enzyme expression system, named the CJ1 system (Korean Patent 10-0620092 B1), instead of employing the typical system.
- the expression levels of OPSS between a pET system comprising a T7 promoter and the CJ1 system comprising a CJ1 promoter were compared given the same conditions. As a result, the CJ1 system showed a higher expression level of OPSS than the pET system.
- the overexpression of OPSS required a low temperature (18° C.) and a long period of time in the pET system, but a high temperature (37° C.) and a short period of time in the pCL-pCJ1 system.
- the pCL-pCJ1 system is used to obtain OPSS.
- the enhancement of the enzyme activity may be achieved using various well-known methods. For example, it can be performed by increasing the number of copies of a gene encoding OPSS, using a strong promoter, or introducing a genetic mutation.
- optimization of the enzymatic conversion of OPSS may be achieved using various methods known in the art.
- the optimization may be based on a full understanding of the characteristics of OPSS, such as the optimal temperature and pH, inhibition against substrates, substrate concentration, heat stability, etc.
- the optimization may be determined by optimal conditions for the enzymatic conversion, such as the optimal OPSS concentration, the optimal balances of the substrates used in terms of concentrations, a preference for sulfur compounds providing SH for the enzymatic conversion, a preference for certain buffers, the influence of ions generated, and cofactors and their optimal concentrations.
- the OPSS enzyme obtained using the above-mentioned method was characterized and on the basis of the determined characteristics, an economically beneficial enzymatic conversion process that has a high conversion rate of cysteine from OPS, with the guarantee of enzyme stability, was developed.
- the reaction temperature can be set from 37° C. to 80° C.
- Ape-OPSS SEQ ID NO: 6
- Msm-T SEQ ID NO: 4
- 0.001-2 mM PLP pyridoxal-5′-phosphate
- 0.001-100 mM DTT may be used in the enzymatic conversion.
- the cysteine conversion rate was 2.3-fold increased in the presence of 25 mM DTT or 0.2 mM PLP.
- treatment with DTT or PLP brought about an improvement in the cysteine conversion rate of step 2).
- the addition of the cofactor was set to a reasonable level in consideration of the increased production cost and the increased conversion rate (Table 11).
- the reaction conditions for OPSS may vary depending on the kinds and concentration of the OPS used.
- pure OPS commercially available
- OPS purified from the culture prepared in step 1) and the OPS-containing culture of step 1) were used under various conditions to provide the optimal conversion rates.
- the cysteine conversion rate varied depending on the kind and concentration of OPSS and the reaction temperature and the kind and concentration of OPS ( FIGS. 5 and 6 , and Table 16).
- the method of the present invention may further comprise isolating and purifying the cysteine produced in step 2). After the enzymatic conversion, cysteine can be isolated and purified from the culture medium using a method well known in the art.
- cysteine derivatives may be chemically synthesize cysteine derivatives from cysteine using a well known method.
- Cysteine may be readily reacted with an acetylation agent to give NAC (N-acetylcysteine) and with haloacetic acid under basic conditions to give SCMC (S-carboxymethylcysteine).
- NAC N-acetylcysteine
- SCMC S-carboxymethylcysteine
- the OPS broth obtained through microbial fermentation is used as a substrate for synthesizing cysteine.
- the OPS broth obtained by microbial fermentation has economical advantages over commercially available pure OPS in that the OPS broth can be used without having to be additionally purified and the cofactor PLP necessary for the conversion can be obtained from the fermented culture.
- a conversion process was developed which ensures a cysteine conversion rate of as high as 80% when 50 ⁇ g/ml Msm-T was used under reaction conditions of a 50 mM OPS broth or a 60 mM purified OPS broth, 100 mM Na 2 S or 120 mM Na 2 S, and 0.2 mM PLP. It should be appreciated to those skilled in the art that the enzymatic conversion using highly active enzymes can easily be optimized and scaled up.
- the present invention provides a recombinant microorganism which is reduced the activity of SerB for the production of OPS.
- the recombinant microorganism for the production of OPS is the microorganism deposited under accession No. KCCM11212P.
- Corynebacterium glutamicum 13032 was modified by deleting the serB gene (SEQ ID NO: 7, EC 3.1.3.3) encoding phosphoserine phosphatase, which catalyses the synthesis of L-serine from O-phosphoserine, therefrom. To this end, a fragment for inactivation of serB was constructed.
- primers were designed for the preparation of the recombinant strain 13032- ⁇ serB of the present invention.
- the serB sequence of Corynebacterium glutamicum 13032 was obtained with reference to the data of the NIH GenBank, and primers SEQ ID NOS: 9 to 14 were synthesized on the basis of the serB sequence.
- pDC- ⁇ serB plasmid in which the open reading frame of serB was internally disrupted was constructed and adopted for the preparation of a site-specific serB gene deletion in Corynebacterium glutamicum mutant strain.
- the internal gene disruption of the pDC- ⁇ serB was generated by crossover PCR using primer pairs of SEQ ID NOS: 9 and 10 and SEQ ID NOS: 11 and 12, with the genomic DNA of Corynebacterium glutamicum ATCC13032 serving as a template, and introducing the PCR product into a pDC vector.
- the resulting recombinant plasmid was transformed into wild-type Corynebacterium glutamicum by electroporation (van der Rest et al. 1999).
- the plasmid was introduced into the chromosome by primary recombination (crossing over), followed by secondary recombination (crossing over) to excise the original serB from the chromosome.
- Corynebacterium glutamicum transformants containing the deletion mutation of serB was analyzed by diagnostic PCR using a pair of gene-specific primers SEQ ID NOS: 13 and 14.
- the recombinant strain was named CB01-0047.
- the mutant strain CB01-0047 resulting from the deletion of serB from Corynebacterium glutamicum 13032, which was anticipated to accumulate O-phosphoserine, was spread over BHIS plates and incubated overnight in a 30° C. incubator.
- the CB01-0047 strain was observed to grow very slowly in the titer medium. This growth retardation was not improved even upon the addition of an L-glycine supplement. However, the growth was increased in the presence of L-serine, but a slight increase in the production of O-phosphoserine compared to the wild-type was observed. The results are summarized in Table 3, below.
- E. coli was modified by deleting the serB gene (SEQ ID NO: 8) encoding phosphoserine phosphatase, which catalyses the synthesis of L-serine from O-phosphoserine, therefrom.
- the deletion mutant E. coli K12 was prepared using the one-step inactivation method (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000) to delete an antibiotic-resistant maker gene.
- To prepare the serB deletion strain first, PCR was performed on a pKD3 plasmid (Datsenko K A and Wanner B L, Proc. Natl. Acad.
- the PCR product was (introduced into competent cells of pKD46 containing E. coli K12 (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000; GenBank No. AY048746) by electroporation. Thereafter, strains that showed resistance to chloramphenicol were subjected to PCR to confirm the deletion of serB, and then transformed with pCP20 (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000) to remove the antibiotic-resistant marker. The resulting mutant strain was named CA07-0012.
- initiation codon of serB was modified to lower phosphoserine phosphatase activity as follows.
- the wild-type serB gene with ATG as an initiation codon was obtained by PCR with the genomic DNA of E. coli W3110 serving as a template.
- a mutant serB with CTG as an initiation codon was constructed by sewing PCR.
- a pair of primes of SEQ ID NOS: 17 and 18 was used in the PCR for amplifying the wild-type serB while pairs of primers of SEQ ID NOS: 19 to 20 were employed for PCR amplification of the mutant serB.
- the PCR products was treated with HindIII and cloned into pccBAC1 (Epicentre) at the HindIII restriction site to construct pccBAC1-Pself-ATG-serB, and pccBAC1-Pself-CTG-serB respectively.
- the wild-type and the mutant serB vector was introduced into CA07-0012 to compare the phosphoserine phosphatase activity.
- CA07-0012 was cultured for 48 hours in the titer medium of Table 4 additionally contained 1 g/L L-glycine. The results are summarized in Table 6, below.
- OPS Sulfhydrylase OPSS
- Aeropyrum pernix, Mycobacterium tuberculosis , and Trichomonas vaginalis are reported to have O-phosphoserine sulfhydrylase (OPSS), an enzyme that employs O-phospho-L-serine (OPS), instead of O-acetyl serine (OAS) in E. coli , as a substrate for the synthesis of cysteine (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Burns K E, Baumgart S, Dorrestein P C, Zhai H, McLafferty F W and Begley T P, J. Am. Chem.
- OPSS O-phosphoserine sulfhydrylase
- OAS O-acetyl serine
- a pET28a vector system (Novagen), which is typically used for enzyme expression, was constructed.
- Each templates and primers for use in cloning the five different OPS sulfhydrylase genes and the resulting recombinant plasmids are summarized in Table 7, below. Suitable combinations of the templates and the primers, as given in Table 7, were used for PCR for amplifying respective OPSS genes.
- the PCR products and the pET28a vector were digested with NdeI and HindIII (37° C. for 3 hours). Each of the gene fragments was ligated to the digested pET28a vector (Novagen). Base sequencing confirmed the construction of the expression vectors carrying the each OPSS genes.
- the enzyme expression vectors were introduced into E. coli (DE3) to produce strains capable of expressing five OPSS enzymes. Enzyme names are given in Table 7, below.
- OPS OPS sulfhydrylase
- OPS O-phosphoserine
- OPS sulfhydrylase enzymes derived from Aeropyrum pernix and Mycobacterium tuberculosis H37Rv, which were previously reported (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Westrop G D, Goodall G, Mottram J C and Coombs G H, J. Biol. Chem., 281: 25062-25075, 2006), were confirmed to have the activity of using OPS as a substrate to synthesize cysteine.
- MC2 155-derived OPS sulfhydrylase which was obtained by screening amino acid homology with the Mtb-OPSS enzyme, was first found. As seen in the data of Table 9, the conversion rate from OPS into cysteine of Ape-OPSS reached near 100% in one hour. The final conversion rate of the Msm-OPSS enzyme, which was newly selected through enzyme screening on the basis of previously reported Mycobacterium tuberculosis H37Rv-derived OPSS, was 43.7% that was 4.3 times as high as that of Mtb-OPSS. On the other hand, the novel Nocardia farcinica IFM 10152-derived OPS sulfhydrylase, obtained by the homology screening, exhibited insufficient activity of converting O-phosphoserine into cysteine.
- Mtb-OPSS Mycobacterium tuberculosis H37Rv-derived OPSS
- Msm-T was also obtained from Msm-OPSS (SEQ ID NO: 3) that shares an amino acid homology with Mtb-OPSS.
- Expression vectors carrying the two enzyme mutants were constructed.
- pfu PCR was performed on the genomic DNA of Mycobacterium tuberculosis H37Rv or Mycobacterium smegmatis in the presence of a pair of primers of SEQ ID NOS: 31, 32, 33 and 34.
- the OPSS gene fragments thus obtained were treated with NdeI and HindIII and were cloned into the pET28a vector digested with the same restriction enzymes to construct recombinant expression vectors named pET28a-Mtb-T and pET28a-Msm-T, respectively.
- the recombinant expression vectors were introduced into E. coli (DE3).
- the expression of the two mutant OPSS enzymes was confirmed by 14% SDS PAGE.
- the two mutant OPSS enzymes are purified and expressed in the same conditions as in Example 5.
- Mtb-T SEQ ID NO: 5
- Msm-T SEQ ID NO: 4
- Mtb-T and Msm-T were obtained. They were evaluated for enzymatic activity by measuring final cysteine conversion rates. Enzymatic activity was assayed in the same condition and manner as in Example 6. The produced cysteine was quantitatively analyzed using the Gaitonde method.
- Msm-T being devoid of the five C-terminal amino acid residues of Mycobacterium smegmatis str.
- MC2 155-derived OPSS allowed the conversion of cysteine from the substrate at a rate of 100% in one hour.
- O-phosphoserine sulfhydrylase OPSS
- OPSS O-phosphoserine sulfhydrylase
- cysteine conversion rate of Msm-T was measured in the absence or presence of PLP (pyridoxal-5′-phosphate) and DTT (dithiothreitol).
- PLP pyridoxal-5′-phosphate
- DTT dithiothreitol
- the cysteine thus produced was quantitatively analyzed using the Gaitonde method. As seen in Table 11, the cysteine conversion rate in the presence of both PLP and DTT was 2.3 times as large as that in the absence of both PLP and DTT. Thus, both PLP and DTT were observed to have a positive influence on the conversion.
- the cysteine conversion rates of Ape-OPSS and Msm-T according to temperatures were examined.
- the enzymatic activity at 37° C. and 60° C. was measured 2, 5, 10, 30, and 60 min after reaction.
- the reaction was conducted under the condition of 100 mM HEPES (pH 7.4), 5 mM OPS, 10 mM Na 2 S, 0.2 mM PLP, and CysM 50 ⁇ g/mL.
- the amount of produced cysteine was determined using the Gaitonde method.
- Ape-OPSS showed a faster initial reaction rate at 37° C. as well as higher reactivity at 60° C. than did Msm-T.
- Ape-OPSS and Msm-T were analyzed for heat stability. Each of the enzymes was diluted to a concentration of 2 mg/mL in an OPS broth and thermally treated at 37° C. and 60° C. for 10, 30, 60, 120, and 240 min, followed by reaction at 37° C. for 30 min under the condition of 5 mM OPS, 10 mM Na 2 S, 0.2 mM PLP, and 100 mM HEPES (pH 7.4). For this reaction, 10 ⁇ g/mL Ape-OPSS and 50 ⁇ g/mL Msm-T were employed. The amounts of the produced cysteine were measured using the Gaitonde method. Ape-OPSS was observed to retain its intact activity in spite of heat treatment at 60° C. for 4 hours while the activity of Msm-T was maintained at 37° C., but decreased by 50% upon heat treatment at 60° C. for 30 min. The results are given in Table 12, below.
- the cysteine conversion rates of Ape-OPSS and Msm-T according to pH were measured.
- Ape-OPSS and Msm-T each having a concentration of 50 ⁇ g/mL, were subjected to reaction at 37° C. for 10 min.
- K-phosphate buffer with a pH of 6.4/7.0/7.4/8.0, Tris-HCl buffer with a pH of 7.0/7.4/8.0/8.5/8.8, and Na-carbonate buffer with a pH of 8.0/8.5/9.0/10.0 were used.
- the quantitative analysis of the produced cysteine was conducted using the Gaitonde method. As seen in FIG.
- Msm-T exhibited the highest activity at a pH of from 8.0 to 9.0 irrespective of buffer.
- Ape-OPSS its highest activity was detected in K-phosphate (pH 7.4), with an optimal pH differing from one buffer to another.
- PCR was performed using primers of SEQ ID NOS: 35 and 36, with the pET28a-Msm-T vector serving as a template.
- the PCR product thus obtained was treated with EcoRV and HindIII and cloned into pCL-P(CJ1) to construct a recombinant vector named pCL-P(CJ1)-Msm-T.
- strains for expressing the enzyme were prepared. The pET system was introduced into Rosetta (DE3) while the pCL-Pcj1 system used the K12G strain.
- Single colonies taken from LB plates were inoculated into 5 mL of LB broth and cultured at 37° C. for 16 hours while shaking at 200 rpm. These cultures were transferred to 25 mL of fresh LB broth containing kanamycine or spectinomycine and 0.2% glucose (in 250 mL flasks) and incubated to an OD 600 of 0.5-0.6, immediately after which 1 mM IPTG was added to the media to induce the enzymes to be expressed. During incubation at 37° C. while shaking at 200 rpm, the expression levels of the enzyme were measured at various culture times (8, 16, 24 hours). The enzyme expression levels of the two systems were analyzed on 14% SDS PAGE ( FIG. 4 ).
- the conversion rates from purified OPS to cysteine of Msm-T and Ape-OPSS were determined.
- 60 mM OPS purified from OPS fermentation broth was reacted with 120 mM Na 2 S at 37° C. or 70° C. for 30, 60, 90, and 120 min.
- the reaction was conducted only at 37° C. for Msm-T, but at both 37° C. and 70° C. for Ape-OPSS.
- the amounts of the produced cysteine were measured using the Gaitonde method.
- a purified OPS fermentation broth served well as a substrate for the enzymatic conversion into cysteine.
- the conversion rate of Ape-OPSS was increased at 70° C. even upon the use of the purified OPS fermentation broth.
- the cysteine conversion rates of Msm-T and Ape-OPSS were measured according to the concentrations of the enzymes.
- 50 mM of OPS fermentation broth was reacted with 5 ⁇ g/mL or 50 ⁇ g/mL of each of Msm-T and Ape-OPSS at 37° C.
- the amounts of the produced cysteine were measured using the Gaitonde method. As seen in FIG. 6 , the highest conversion rate was detected in 50 ⁇ g/mL Msm-T.
- the activity of Msm-T was higher than that of Ape-OPSS.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides methods for the production of cysteine or derivates thereof by culturing a microorganism having reduced activity of endogenous phosphoserine phosphatase. The O-phosphoserine produced by such an organism can then be reacted with a sulfide in the presence of a sulfydrylase or a microorganism expressing a sulfhydrylase to produce cysteine or a derivative thereof. Microorganisms having the properties noted above are also provided herein.
Description
- This application claims the priority benefit of Korean Patent Application Nos. 10-2011-0086081, filed Aug. 26, 2011 and 10-2010-0102664, filed Oct. 20, 2010. The contents of these patent applications are incorporated herein by reference in their entireties.
- The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is HANO—004—00US_ST25.txt. The text file is 28 KB, was created on Oct. 20, 2011, and is being submitted electronically via EFS-Web.
- The present invention relates to a method for production of cysteine or its derivatives using O-phosphoserine as an intermediate and recombinant microorganism for use in production of O-phosphoserine.
- L-cysteine is an amino acid that plays an important role in sulfur metabolism of all living organisms. It is used in the biosynthesis of proteins, such as hair keratin, glutathione, biotin, methionine and other sulfur-containing metabolites as well as serving as a precursor of coenzyme A. In addition, the biosynthesis of cysteine is known to be closely associated with the biosynthesis of other amino acids including L-serine, L-glycine, and L-methionine. Industrially, L-cysteine and its derivatives find applications in a variety of fields including the pharmaceutical industry (for treatment of bronchial diseases), the cosmetics industry (in hair shampoo, compositions for permanent waves), and the food industry (antioxidants, flavorant enhancers, dough aids, etc.).
- L-cysteine was once obtained industrially by acid hydrolysis of human hairs or animal feathers (Biotechnology of the Amino Acids Production edited by Ko Aida, p 217-223, 1986). However, not only does the production of cysteine from hairs or feathers ensure a yield of as low as 7˜8%, but also the use of hydrochloric acid or sulfuric acid produces a lot of waste resulting in environmental pollution. Further, extraction from hairs or feathers may induce the user to have a strong aversion thereto. These problems have caused a push for the development of environmentally friendly production processes of L-cysteine. The main contemporary route involves fermentation utilizing microorganisms.
- Representative among the microbial production of L-cysteine is 1) the biological conversion of D,L-ATC using a microorganism (Ryu O H, Ju J Y and Shin C S, Process Biochem., 32:201-209, 1997). This conversion process is, however, difficult to apply industrially due to the low solubility of the precursor D,L-ATC. 2) Another method of L-cysteine production is direct fermentation using E. coli (Patent No. EP0885962B; Wada M and Takagi H, Appl. Microbiol. Biochem., 73:48-54, 2006). Excessive accumulation of L-cysteine within microorganisms incurs intracellular toxicity, exhibiting a limitation in the production of L-cysteine at a high concentration. To overcome this drawback, L-cysteine-exporting proteins are employed, but there have been no significant improvements in productivity.
- Referring to the biosynthesis pathway of L-cysteine in microorganisms and plants, O-acetyl-serine (OAS) acts as an intermediate precursor providing the carbon backbone of L-cysteine (Kredich N M and Tomkins G M, J. Biol. Chem., 241: 4955-4965, 1966). The enzyme O-acetylserine sulfhydrylase (OASS), using hydrogen sulfide as a sulfur donor, catalyses the conversion of O-acetylserine to cysteine. Alternatively, SO4 may be reduced to thiosulfate for use as a sulfur donor in cysteine production (Nakamura T, Kon Y, Iwahashi H and Eguchi Y, J. Bacteriol., 156: 656-662, 1983). Therefore, cystein may be produced using microorganisms accumulating OAS and OASS using various sulfur donors (U.S. Pat. No. 6,579,705). The cysteine biosynthesis pathway via OAS uses the two enzymes of serine acetyltransferase (CysE), which catalyzes the conversion of OAS from serine, and cysteine synthase (CysK), which catalyzes the conversion of OAS to cysteine. Among them, serine acetyltransferase (CysE) is highly sensitive to feedback inhibition by the final product cysteine (Wada M and Takagi H, Appl. Microbiol. Biochem., 73:48-54, 2006).
- Leading to the present invention, the present inventors found out the existence of O-phosphoserine sulfhydrylase (OPSS) in Aeropyrum pernix, Mycobacterium tuberculosis, and Trichomonas vaginalis that takes an O-phospho-L-serine (OPS)-specific pathway, rather than the OAS-specific pathway, to synthesize L-cysteine through intensive research (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Burns K E, Baumgart S, Dorrestein P C, Zhai H, McLafferty F W and Begley T P, J. Am. Chem. Soc., 127: 11602-11603, 2005; Westrop G D, Goodall G, Mottram J C and Coombs G H, J. Biol. Chem., 281: 25062-25075, 2006) and that the OPSS of M. tuberculosis, can use Na2S as a sulfur donor in converting OPS to cysteine even in the absence of the additional enzymes when five C-terminal amino acid residues are removed therefrom (Argen D, Schnell R and Schneider G, FEBS letters, 583: 330-336, 2009). In the present invention, a microorganism is mutated to accumulate OPS therein, following incubation to convert OPS into cysteine in the presence of the OPSS enzyme. Nowhere has this method been previously described.
- It is an object of the present invention to provide a method for producing cysteine or a derivative thereof. It is another object of the present invention to provide a recombinant microorganism for the production of O-phosphoserine.
- The method of the present invention in which O-phosphoserine is produced at high yield by a recombinant microorganism and is used for conversion into cysteine, as it is, is more friendly to the environment and ensures higher efficiency in the production of cysteine than do chemical synthesis methods. The cysteine and its derivatives produced by the fermentation and bioconversion of the present invention can be widely used in the production of animal and human foods and food additives.
-
FIG. 1 is a schematic diagram showing the accumulation of O-phosphoserine by microbial fermentation and the enzymatic conversion of the accumulated O-phosphoserine into L-cysteine. -
FIG. 2 is a graph showing the activity of OPS sulfhydrylase according to temperatures. -
FIG. 3 is a set of graphs showing pH sensitivity of OPS sulfhydrylase. -
FIG. 4 is a photograph showing the expression level of Msm-T in a pET system and a pCL-Pcj1 system as analyzed by SDS PAGE. -
FIG. 5 is a graph showing the enzymatic activity of OPS sulfhydrylase to convert purified OPS fermentation broth into cysteine. -
FIG. 6 is a graph showing the enzymatic activity of OPS sulfhydrylase to convert OPS fermentation broth into cysteine. - As used herein, the term “cysteine conversion” is intended to refer to the catalytic reaction of O-phosphoserine sulfhydrylase (OPSS) which results in the conversion of the substrate O-phosphoserine (OPS) into the product cysteine, that is, it refers to the catalytic reaction of converting OPS into cyteine.
- As used herein, the term “cysteine conversion rate” refers to the percentage of the amount of the product cysteine to the amount of the starting material OPS. Under optimal reaction conditions, 1 mole of OPS is converted into 1 mole of cysteine. For example, if 100 moles of OPS is converted into 100 moles of cysteine, the cysteine conversion rate is 100%.
- In accordance with an aspect thereof, the present invention provides a method for producing cysteine or a derivative thereof, comprising:
- 1) culturing a recombinant microorganism in which the activity of endogeneous phosphoserine phosphatase (SerB) is reduced, to produce O-sphosphoserine (OPS); and 2) reacting the OPS of step 1) with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism expressing OPSS, to produce cysteine or a derivative thereof.
- The SerB is a protein that has the activity of hydrolyzing OPS into L-serine. Thus, a microorganism which has reduced endogeneous SerB activity is characterized by the accumulation of OPS therein. The SerB is not limited to, may comprise any amino acid sequences, which exhibits SerB activity, and may have preferably the amino acid sequence of SEQ ID NO: 1 or 2. However, as long as it exhibits SerB activity, any amino acid sequence is used, which preferably has a homology of 90% or higher, more preferably 96% or higher, far more preferably 98% or higher, and most preferably 99% or higher with that of SEQ ID NO: 1 or 2. The reduced SerB activity means a decrease in SerB activity, compared to that of a prior-modified strain, and encompasses the disrupting of SerB. Various techniques for reduction of SerB activity are well known in the art. Illustrative examples include the deletion of a chromosomal serB, the introduction of mutation into the chromosomal serB to reduce endogenouse SerB activity, the introduction of mutation into a regulatory region for the serB to reduce endogenouse SerB activity, the substitution of the chromosomal serB with a gene mutated to reduce the endogenouse SerB activity, the introduction of mutation into a regulatory region for the serB to reduce endogenouse SerB activity, and the introduction of an antisense oligonucleotide complementary to a transcript of the serB to inhibit the translation of the mRNA, but methods for reducing the SerB activity are not limited to these. These techniques may be applied to the reducing the activity of other enzymes in the present invention.
- The disruption of endogenous SerB results in the introduction of serine auxotrophy into the recombinant microorganism so that the medium must be supplemented with glycine or serine. Glycine may be provided in the form of purified glycine, a glycine-containing yeast extract, or tryptone. Glycine is contained at a concentration of from 0.1 to 10 g/L, and preferably at a concentration of from 0.5 to 3 g/L. As for serine, it may be provided in the form of purified serine, a serine-containing yeast extract or tryptone. Its concentration in the culture medium ranges from 0.1 to 5 g/L, and preferably from 0.1 to 1 g/L.
- Preferably, when cultured in a glycine- or serine-containing medium, mutant Corynebacterium glutamicum or E. coli in which the activity of endogeneous SerB was disrupted was found to produce a higher amount of OPS, compared to the wild-type (see Tables 2, 3, 4 and 5).
- The recombinant microorganism of the present invention refers to any microorganism which is modified to reduce SerB activity, thus producing OPS at an elevated level. If this condition is satisfied, any microorganism, whether prokaryotic or eukaryotic, falls within the scope of the present invention. Representative among them are enterobacteria or coryneform bacteria. Examples of the microorganisms useful in the present invention include Escherichia sp., Erwinia sp., Serratia sp., Providencia sp., Corynebacterium sp., and Brevibacterium sp. Preferable are Escherichia sp. and Corynebacterium sp, with more preference given for Escherichia sp. and with the highest preference being for E. coli.
- In an embodiment, the strain capable of producing OPS was named E. coli CA07-0012, and deposited with the Korean Culture Center of Microorganisms, located at 361-221,
Hongje 1, Seodaemun, Seoul, Korea, on Oct. 12, 2011 under accession number KCCM11212P. - As used herein, the term “culturing” is intended to mean growing microorganisms under artificially controlled conditions. A culturing procedure may be conducted using a suitable medium and culturing conditions well known in the art. Those skilled in the art can readily control the culturing procedure to correspond to the strains employed. For example, it may be performed in a batch type, in a continuous type, or in a fed-batch type, but is not limited thereto.
- In addition, the culture medium contains a carbon source. Examples of the carbon source include saccharides and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch and cellulose, oils and fats such as soybean oil, sunflower oil, castor oil and coconut oil, fatty acis such as palmitic acid, stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid. These carbon sources may be present solely or in combination in the culture medium. As a nitrogen source, an organic material such as peptone, yeast extract, meat juice, malt extract, corn steep liquor, soybean, and wheat protein, or an inorganic nitrogen compound such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate may be contained in the culture medium. These nitrogen sources may be used solely or in combination. The medium may contain potassium dihydrogen phosphate, potassium phosphate, or corresponding sodium salts as a phosphorous source. The medium may contain metallic salts such as magnesium sulfate or iron sulfate. The culture medium may also contain amino acids, vitamins and suitable precursors. The nutrients may be added in a batch manner or a continuous manner to the medium.
- A compound such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid may be added in a suitable manner to the culture medium during culturing to adjust the pH of the culture. In addition, during culturing, an anti-foaming agent such as fatty acid polyglycol ester is used to suppress the formation of foam. Further, in order to maintain the culture medium in an aerobic condition, oxygen or oxygen-containing gas can be injected into the culture medium. For an anaerobic or microaerobic condition, nitrogen, hydrogen, or carbon dioxide is provided without aeration. The culture medium may be typically maintained at a temperature of from 27° C. to 37° C. and preferably at a temperature of from 30° C. to 35° C. As for the culture period, it may be maintained until the product of interest is obtained in a desired amount, and preferably it ranges from 10 to 100 hours.
- For further collection and recovery of the OPS produced during the culturing step from the culture medium, a suitable method well known in the art may be selected depending on the type of culture, be it a batch, continuous or fed-batch culture.
- In the method of the present invention, step 2) addresses the reaction of the OPS of step 1) with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism expressing OPSS, to induce the conversion of O-phosphoserine into cysteine or its derivatives.
- The sulfide may be provided in a liquid or gas form as well as in a solid form typically used in the art, because of the difference in pH, pressure and/or solubility. So long as it may be converted to a thiol group (SH), any sulfur compound such as sulfide (S2−) or thiosulfate (S2O3 2−) may be used in the present invention. Preferably, Na2S, NaSH, H2S, (NH4)2S, NaSH and Na2S2O3, all of which can provide a thiol group for OPS, may be used. In the reaction, one thiol group is supplied to one OPS molecule to afford one molecule of cysteine or a derivative thereof. In this enzymatic conversion, a sulfide may be preferably added at a molar concentration 0.1 to 3 times and more preferably 1 to 2 times as high as that of OPS used. In light of the economy, a thiol group-providing sulfide and OPS are most preferably used at a molar ratio of 1:1. In one embodiment of the present invention, Na2S was used as the source of sulfur. Na2S was added at a
molar concentration 1 to 3 times as high as that of OPS used in the conversion reaction. Preferably, it is fed at a molar concentration twice as high as that of OPS to effectively convert OPS into cysteine (Table 15). - As used herein, the term “O-phosphoserine sulfhydrylase (OPSS)” refers to an enzyme that catalyzes the transfer of a thiol group (SH) to OPS(O-phosphoserine) to convert OPS into cysteine. The enzyme was first found in Aeropyrum pernix, Mycobacterium tuberculosis, and Trichomonas vaginalis (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Burns K E et al., J. Am. Chem. Soc., 127: 11602-11603, 2005). The above mentioned enzymes have the amino acid sequences of SEQ ID No: 3 and 6.
- As used herein, the term “mutant” refers to a culture or an individual that shows an inheritable or non-heritable alteration in phenotype. When used in conjunction with OPSS, the term “mutant” is intended to mean an OPSS enzyme which is genetically altered such that its activity can be effectively enhanced, compared to the wild-type.
- In the present invention, the OPSS mutant can be constructed by deleting, substituting or adding a part of a nucleotide sequence encoding OPSS. According to one embodiment of the present invention, an OPSS enzyme with enhanced activity was prepared by deleting five C-terminal amino acid residues of the OPSS enzyme of Mycobacterium smegmatis. The mutant enzymes have the amino acid sequences of SEQ ID NO: 4 and 5.
- The OPSS mutant can be obtained in E. coli, widely used for enzyme expression, using gene synthesis techniques based on codon optimization by which enzymes of interest can be obtained in high yield. Alternatively, screening methods of useful enzyme resources based on the bioinformatics of massive amounts of genetic information about microorganisms may be used to obtain the OPSS mutant. In one embodiment of the present invention, OPSS enzymes that utilize OPS as a substrate to synthesize cysteine were selected from various microbes by screening the homology of amino acid sequences. In this regard, cell pellets obtained using a medium and culture conditions that were suitable in the art were lyzed, followed by the purification of the supernatant containing the enzyme to afford the OPSS enzyme (Table 7).
- In addition, a high-yield expression system was developed for obtaining the OPSS enzyme economically. A pET vector employing a T7 promoter is well known in the art. However, the present inventors developed an enzyme expression system, named the CJ1 system (Korean Patent 10-0620092 B1), instead of employing the typical system. In one embodiment of the present invention, the expression levels of OPSS between a pET system comprising a T7 promoter and the CJ1 system comprising a CJ1 promoter were compared given the same conditions. As a result, the CJ1 system showed a higher expression level of OPSS than the pET system. In addition, the overexpression of OPSS required a low temperature (18° C.) and a long period of time in the pET system, but a high temperature (37° C.) and a short period of time in the pCL-pCJ1 system. Preferably, the pCL-pCJ1 system is used to obtain OPSS.
- The enhancement of the enzyme activity may be achieved using various well-known methods. For example, it can be performed by increasing the number of copies of a gene encoding OPSS, using a strong promoter, or introducing a genetic mutation.
- Optimization of the enzymatic conversion of OPSS may be achieved using various methods known in the art. For example, the optimization may be based on a full understanding of the characteristics of OPSS, such as the optimal temperature and pH, inhibition against substrates, substrate concentration, heat stability, etc. In addition, the optimization may be determined by optimal conditions for the enzymatic conversion, such as the optimal OPSS concentration, the optimal balances of the substrates used in terms of concentrations, a preference for sulfur compounds providing SH for the enzymatic conversion, a preference for certain buffers, the influence of ions generated, and cofactors and their optimal concentrations.
- In one embodiment of the present invention, the OPSS enzyme obtained using the above-mentioned method was characterized and on the basis of the determined characteristics, an economically beneficial enzymatic conversion process that has a high conversion rate of cysteine from OPS, with the guarantee of enzyme stability, was developed. In the enzymatic conversion process, the reaction temperature can be set from 37° C. to 80° C. In detail, Ape-OPSS (SEQ ID NO: 6), belonging to Archea, exhibits increased enzymatic activity at 60° C. compared to 37° C., and the enzyme itself is highly stable to heat, with optimal reactivity at 60° C. On the other hand, Msm-T (SEQ ID NO: 4) exhibits optimal activity at 37° C. and is relieved the activity to heat treatment at 60° C. The OPSS enzyme was observed to have enzymatic activity over a pH range of 6.0 to 10.0. Ape-OPSS showed optimal activity at pH 7.4. With the appearance of optimal activity at a pH of from 8.0 to 9.0, Msm-T showed stability over a wider pH range, compared to Ape-OPSS (Tables 9 and 12, and
FIGS. 2 and 3 ). - As a cofactor, 0.001-2 mM PLP (pyridoxal-5′-phosphate) or 0.001-100 mM DTT may be used in the enzymatic conversion. In one embodiment of the present invention, the cysteine conversion rate was 2.3-fold increased in the presence of 25 mM DTT or 0.2 mM PLP. As such, treatment with DTT or PLP brought about an improvement in the cysteine conversion rate of step 2). The addition of the cofactor was set to a reasonable level in consideration of the increased production cost and the increased conversion rate (Table 11).
- The reaction conditions for OPSS may vary depending on the kinds and concentration of the OPS used. In one embodiment of the present invention, pure OPS (commercially available), OPS purified from the culture prepared in step 1), and the OPS-containing culture of step 1) were used under various conditions to provide the optimal conversion rates. As a result, the cysteine conversion rate varied depending on the kind and concentration of OPSS and the reaction temperature and the kind and concentration of OPS (
FIGS. 5 and 6 , and Table 16). - The method of the present invention may further comprise isolating and purifying the cysteine produced in step 2). After the enzymatic conversion, cysteine can be isolated and purified from the culture medium using a method well known in the art.
- Those skilled in the art may chemically synthesize cysteine derivatives from cysteine using a well known method. Cysteine may be readily reacted with an acetylation agent to give NAC (N-acetylcysteine) and with haloacetic acid under basic conditions to give SCMC (S-carboxymethylcysteine). These cysteine derivatives are used as materials in medicines that treat coughs, bronchitis, bronchial asthma, and sore throat.
- In the present invention, the OPS broth obtained through microbial fermentation is used as a substrate for synthesizing cysteine. The OPS broth obtained by microbial fermentation has economical advantages over commercially available pure OPS in that the OPS broth can be used without having to be additionally purified and the cofactor PLP necessary for the conversion can be obtained from the fermented culture.
- In one embodiment of the present invention, a conversion process was developed which ensures a cysteine conversion rate of as high as 80% when 50 μg/ml Msm-T was used under reaction conditions of a 50 mM OPS broth or a 60 mM purified OPS broth, 100 mM Na2S or 120 mM Na2S, and 0.2 mM PLP. It should be appreciated to those skilled in the art that the enzymatic conversion using highly active enzymes can easily be optimized and scaled up.
- In accordance with another aspect thereof, the present invention provides a recombinant microorganism which is reduced the activity of SerB for the production of OPS. Preferably, the recombinant microorganism for the production of OPS is the microorganism deposited under accession No. KCCM11212P.
- A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed to limit the present invention.
- Corynebacterium glutamicum 13032 was modified by deleting the serB gene (SEQ ID NO: 7, EC 3.1.3.3) encoding phosphoserine phosphatase, which catalyses the synthesis of L-serine from O-phosphoserine, therefrom. To this end, a fragment for inactivation of serB was constructed. In this regard, primers were designed for the preparation of the recombinant strain 13032-ΔserB of the present invention. First, the serB sequence of Corynebacterium glutamicum 13032 was obtained with reference to the data of the NIH GenBank, and primers SEQ ID NOS: 9 to 14 were synthesized on the basis of the serB sequence. For the site-specific gene disruption, a pDC vector which cannot replicate in Corynebacterium glutamicum was employed. A pDC-ΔserB plasmid in which the open reading frame of serB was internally disrupted was constructed and adopted for the preparation of a site-specific serB gene deletion in Corynebacterium glutamicum mutant strain. The internal gene disruption of the pDC-ΔserB was generated by crossover PCR using primer pairs of SEQ ID NOS: 9 and 10 and SEQ ID NOS: 11 and 12, with the genomic DNA of Corynebacterium glutamicum ATCC13032 serving as a template, and introducing the PCR product into a pDC vector. The resulting recombinant plasmid was transformed into wild-type Corynebacterium glutamicum by electroporation (van der Rest et al. 1999). The plasmid was introduced into the chromosome by primary recombination (crossing over), followed by secondary recombination (crossing over) to excise the original serB from the chromosome.
- After completion of the secondary recombination, the Corynebacterium glutamicum transformants containing the deletion mutation of serB was analyzed by diagnostic PCR using a pair of gene-specific primers SEQ ID NOS: 13 and 14. The recombinant strain was named CB01-0047.
- The mutant strain CB01-0047, resulting from the deletion of serB from Corynebacterium glutamicum 13032, which was anticipated to accumulate O-phosphoserine, was spread over BHIS plates and incubated overnight in a 30° C. incubator.
- Afterwards, the colonies appearing on the BHIS plates were inoculated in 25 mL of a titer medium shown in Table 1 using a platinum loop and then incubated at 30° C. for 48 hours with shaking at 200 rpm. The results are summarized in Table 2, below.
-
TABLE 1 Composition Amount (per liter) Glucose 100 g KH2PO4 1.1 g (NH4)2SO4 45 g MgSO4•7H2O 1.2 g HSM 20 g Trace elements 20 ml Calcium carbonate 30 g pH 7.2 Trace elements Biotin 0.09 g Thiamine 0.45 g Ca-Panthenate 0.45 g NCA 3 g FeSO4•7H2O 9 g MnSO4•4H2O 9 g ZnSO4•7H2O 0.045 g CuSO4•5H2O 0.045 g -
TABLE 2 Sugar O-phosphoserine Strain OD 562 nm consumed (g/L) (g/L) C. glutamicum 25 100 0.02 13032 CB01-0047 6.5 23 0.07 - The CB01-0047 strain was observed to grow very slowly in the titer medium. This growth retardation was not improved even upon the addition of an L-glycine supplement. However, the growth was increased in the presence of L-serine, but a slight increase in the production of O-phosphoserine compared to the wild-type was observed. The results are summarized in Table 3, below.
-
TABLE 3 A.A. (amino OD Sugar O-phosphoserine Strain acids) added 562 nm consumed (g/L) (g/L) CB01-0047 — 6.3 21 0.09 L-Glycine 6.9 22 0.09 L-Serine 24.5 100 0.05 - E. coli was modified by deleting the serB gene (SEQ ID NO: 8) encoding phosphoserine phosphatase, which catalyses the synthesis of L-serine from O-phosphoserine, therefrom. The deletion mutant E. coli K12 was prepared using the one-step inactivation method (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000) to delete an antibiotic-resistant maker gene. To prepare the serB deletion strain, first, PCR was performed on a pKD3 plasmid (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000; GenBank No. AY048742) using a pair of primers of SEQ ID NOS: 15 and 16. The PCR product was (introduced into competent cells of pKD46 containing E. coli K12 (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000; GenBank No. AY048746) by electroporation. Thereafter, strains that showed resistance to chloramphenicol were subjected to PCR to confirm the deletion of serB, and then transformed with pCP20 (Datsenko K A and Wanner B L, Proc. Natl. Acad. Sci., 97: 6640-6645, 2000) to remove the antibiotic-resistant marker. The resulting mutant strain was named CA07-0012.
- In addition, the initiation codon of serB was modified to lower phosphoserine phosphatase activity as follows. The wild-type serB gene with ATG as an initiation codon was obtained by PCR with the genomic DNA of E. coli W3110 serving as a template. A mutant serB with CTG as an initiation codon was constructed by sewing PCR. A pair of primes of SEQ ID NOS: 17 and 18 was used in the PCR for amplifying the wild-type serB while pairs of primers of SEQ ID NOS: 19 to 20 were employed for PCR amplification of the mutant serB. The PCR products was treated with HindIII and cloned into pccBAC1 (Epicentre) at the HindIII restriction site to construct pccBAC1-Pself-ATG-serB, and pccBAC1-Pself-CTG-serB respectively. The wild-type and the mutant serB vector was introduced into CA07-0012 to compare the phosphoserine phosphatase activity.
- The phosphoserine phosphatase deficient mutant strain CA07-0012 that was anticipated to accumulate O-phosphoserine, was spread over LB plates and incubated overnight in a 33° C. incubator. Afterwards, the colonies appearing on the LB plates were inoculated in 25 mL of a titer medium shown in Table 4 using a platinum loop and then incubated at 33° C. for 48 hours with shaking at 200 rpm. The results are summarized in Table 5, below.
-
TABLE 4 Composition Amount (per liter) Glucose 40 g KH2PO4 2 g (NH4)2SO4 17 g MgSO4•7H2O 1 g FeSO4•7H2O 10 mg MnSO4•4H2O 10 mg ZnSO4•7H2O 10 mg Yeast extract 2 g Calcium carbonate 30 g pH 6.8 -
TABLE 5 Sugar O-phosphoserine Strain OD 562 nm consumed (g/L) (g/L) E.coli W3110 16 40 0.03 CA07-0012 9.8 16 0.5 CA07-0012/ 20 40 0 pccBAC1-Pself-ATG- serB CA07-0012/ 15 40 0.7 pccBAC-Pself-CTG- serB - To enhance the growth and O-phosphoserine productivity thereof, CA07-0012 was cultured for 48 hours in the titer medium of Table 4 additionally contained 1 g/L L-glycine. The results are summarized in Table 6, below.
-
TABLE 6 Sugar O-phosphoserine Strain OD 562 nm consumed (g/L) (g/L) E.coli W3110 16 40 0.03 CA07-0012 18 40 1.5 - As shown in Table 6, the addition of L-glycine to the culture medium allowed the strain to increase the growth rate and the O-phosphoserine productivity.
- Aeropyrum pernix, Mycobacterium tuberculosis, and Trichomonas vaginalis are reported to have O-phosphoserine sulfhydrylase (OPSS), an enzyme that employs O-phospho-L-serine (OPS), instead of O-acetyl serine (OAS) in E. coli, as a substrate for the synthesis of cysteine (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Burns K E, Baumgart S, Dorrestein P C, Zhai H, McLafferty F W and Begley T P, J. Am. Chem. Soc., 127: 11602-11603, 2005; Westrop G D, Goodall G, Mottram J C and Coombs G H, J. Biol. Chem., 281: 25062-25075, 2006). Based on the report, the present inventors found two types of OPS sulfhydrylase, which converts OPS into cysteine, from Aeropyrum pernix and Mycobacterium tuberculosis H37Rv. Of them, the Mycobacterium tuberculosis H37Rv-derived OPSS enzyme was used for screening amino acid homology. As a result, three types of OPSS were secured from Mycobacterium smegmatis str. MC2 155, Rhodococcus jostii RHA1, and Nocardia farcinica IFM 10152.
- To obtain OPSS from each strain, a pET28a vector system (Novagen), which is typically used for enzyme expression, was constructed. Each templates and primers for use in cloning the five different OPS sulfhydrylase genes and the resulting recombinant plasmids are summarized in Table 7, below. Suitable combinations of the templates and the primers, as given in Table 7, were used for PCR for amplifying respective OPSS genes. The PCR products and the pET28a vector were digested with NdeI and HindIII (37° C. for 3 hours). Each of the gene fragments was ligated to the digested pET28a vector (Novagen). Base sequencing confirmed the construction of the expression vectors carrying the each OPSS genes. The enzyme expression vectors were introduced into E. coli (DE3) to produce strains capable of expressing five OPSS enzymes. Enzyme names are given in Table 7, below.
-
TABLE 7 Enzyme Vector Template Primer Ape-OPSS pET28a-Ape- Synthetic DNA SEQ ID NOS: 21 and 22 OPSS Mtb-OPSS pET28a-Mtb- Mtb genomic SEQ ID NOS: 23 and 24 OPSS DNA Msm-OPSS pET28a-Msm- Msm genomic SEQ ID NOS: 25 and 26 OPSS DNA Rjo-OPSS pET28a-Rjo- Rjo genomic SEQ ID NOS: 27 and 28 OPSS DNA Nfa-OPSS pET28a-Nfa- Nfa genomic SEQ ID NOS: 29 and 30 OPSS DNA - Expression of the enzymes was conducted according to the instructions of the pET system manufacturer (Novagen). Single colonies of each strain from the LB plates were inoculated into 5 mL of LB broth and incubated at 37° C. for 16 hours while shaking at 200 rpm. The cultures were transferred to 25 mL of fresh LB broth (in 250 mL flasks) and incubated to an OD600 of 0.5-0.6 (for 2-3 hours) in the same condition, immediately after which 1 mM IPTG was added to the media to induce the enzymes to be expressed during incubation at 18° C. for 18 hours while shaking at 120 rpm. The enzymes were purified using Ni-NTA columns for His-tag, with the aid of His SpinTrap (GE Healthcare). Of the five OPSS enzymes thus isolated, four were found to be in soluble forms, with one (Rjo-OPSS) being an inclusion body, as analyzed by 14% SDS-PAGE electrophoresis.
- The OPS sulfhydrylase enzymes obtained from the four microorganism strains were assayed for ability to catalyze the conversion of O-phosphoserine (OPS) to cysteine. With regard to assay conditions and methods (cysM enzyme assay), reference was made to previous reports (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Burns K E, Baumgart S, Dorrestein P C, Zhai H, McLafferty F W and Begley T P, J. Am. Chem. Soc., 127: 11602-11603, 2005; Westrop G D, Goodall G, Mottram J C and Coombs G H, J. Biol. Chem., 281: 25062-25075, 2006). The amount of the substrate used is represented by a unit of mL. Assay conditions for enzyme activity are summarized in Table 8, below.
-
TABLE 8 Stock soln Final Conc. Blank OPS sulfhydrase 6x his-enzyme — 40 (50 mg) 1M HEPES 100 mM HEPES 100 100 (pH 7.4) 0.5M Na2S 10 mM Na2S 20 20 10 mM PLP 0.2 mM PLP 20 20 100 mM OPS 5 mM OPS 0 50 DW 790 750 Total 1000 1000 - Reaction solutions excepting of the enzymes were incubated at 37° C. for 5 min, after which 50 mg of purified OPS sulfhydrylase was added to the reaction solution. At predetermined times during incubation at 37° C., 100 mL of the enzyme reactions was taken and mixed with 100 mL of 33.2% TCA to stop the enzymatic reaction. The cysteine concentrations of the enzyme reactions were quantitatively analyzed by measuring absorbance at OD560 according to the Gaitonde method. Cysteine synthesis activities of the four different OPS sulfhydrylase enzymes are summarized in Table 9, below. The cysteine synthesis titers of the OPSS enzymes are expressed as cysteine conversion rates with reaction time.
-
TABLE 9 Cysteine Conversion Rate (%) 10 min 30 min 60 min Ape-OPSS 63.4 89.7 97.4 Mtb-OPSS 1.7 4.8 10.1 Msm-OPSS 12.8 25 43.7 Nfa-OPSS 0.1 0.1 0.2 - The OPS sulfhydrylase enzymes derived from Aeropyrum pernix and Mycobacterium tuberculosis H37Rv, which were previously reported (Mino K and Ishikawa K, FEBS letters, 551: 133-138, 2003; Westrop G D, Goodall G, Mottram J C and Coombs G H, J. Biol. Chem., 281: 25062-25075, 2006), were confirmed to have the activity of using OPS as a substrate to synthesize cysteine. The cysteine synthesis activity of the novel Mycobacterium smegmatis str. MC2 155-derived OPS sulfhydrylase, which was obtained by screening amino acid homology with the Mtb-OPSS enzyme, was first found. As seen in the data of Table 9, the conversion rate from OPS into cysteine of Ape-OPSS reached near 100% in one hour. The final conversion rate of the Msm-OPSS enzyme, which was newly selected through enzyme screening on the basis of previously reported Mycobacterium tuberculosis H37Rv-derived OPSS, was 43.7% that was 4.3 times as high as that of Mtb-OPSS. On the other hand, the novel Nocardia farcinica IFM 10152-derived OPS sulfhydrylase, obtained by the homology screening, exhibited insufficient activity of converting O-phosphoserine into cysteine.
- Mycobacterium tuberculosis H37Rv-derived OPSS (Mtb-OPSS), which catalyzes the conversion of OPS to cysteine with the aid of the additional enzymes mec+ and cysO, is reported to be able to use an S2− containing sulfur source in converting OPS to cysteine even in the absence of the additional enzymes when five C-terminal amino acid residues are removed therefrom (Agren D, Schnell R and Schneider G, FEBS letters, 583: 330-336, 2009). On the basis of this report, Mtb-T (SEQ ID NO: 5), which can rapidly convert OPS in the presence of S2− as a sulfur source, was obtained. Msm-T was also obtained from Msm-OPSS (SEQ ID NO: 3) that shares an amino acid homology with Mtb-OPSS. Expression vectors carrying the two enzyme mutants were constructed. In this regard, pfu PCR was performed on the genomic DNA of Mycobacterium tuberculosis H37Rv or Mycobacterium smegmatis in the presence of a pair of primers of SEQ ID NOS: 31, 32, 33 and 34. The OPSS gene fragments thus obtained were treated with NdeI and HindIII and were cloned into the pET28a vector digested with the same restriction enzymes to construct recombinant expression vectors named pET28a-Mtb-T and pET28a-Msm-T, respectively. The recombinant expression vectors were introduced into E. coli (DE3). The expression of the two mutant OPSS enzymes was confirmed by 14% SDS PAGE. The two mutant OPSS enzymes are purified and expressed in the same conditions as in Example 5. As a result, Mtb-T (SEQ ID NO: 5) and Msm-T (SEQ ID NO: 4) were obtained.
- On the basis of the report that Mycobacterium tuberculosis H37Rv-derived OPSS mutants devoid of five C-terminal amino acid residues show increased affinity for an S2− group-containing sulfur source even in the absence of subsidiary enzymes (Agren D, Schnell R and Schneider G, FEBS letters, 583: 330-336, 2009), Mtb-T and Msm-T were obtained. They were evaluated for enzymatic activity by measuring final cysteine conversion rates. Enzymatic activity was assayed in the same condition and manner as in Example 6. The produced cysteine was quantitatively analyzed using the Gaitonde method.
-
TABLE 10 Cysteine Conversion Rate (%) 10 min 30 min 60 min Mtb-T 9.5 18.6 37.1 Msm-T 20.3 54.6 100 - As seen in Table 10, Msm-T, being devoid of the five C-terminal amino acid residues of Mycobacterium smegmatis str. MC2 155-derived OPSS allowed the conversion of cysteine from the substrate at a rate of 100% in one hour.
- When its amino acid sequence was modified, the O-phosphoserine sulfhydrylase (OPSS) can more effectively catalyze the biosynthesis of L-cysteine.
- To examine the effect of cofactors on the cysteine conversion of OPSS, the cysteine conversion rate of Msm-T was measured in the absence or presence of PLP (pyridoxal-5′-phosphate) and DTT (dithiothreitol). In this regard, the substrates of 50 mM OPS broth and 100 mM Na2S were reacted at 37° C. for 30 min in the presence of 25 mM DTT or 0.2 mM PLP.
- The cysteine thus produced was quantitatively analyzed using the Gaitonde method. As seen in Table 11, the cysteine conversion rate in the presence of both PLP and DTT was 2.3 times as large as that in the absence of both PLP and DTT. Thus, both PLP and DTT were observed to have a positive influence on the conversion.
-
TABLE 11 Msm-T Cysteine Conversion Rate (%) (−) PLP, (−) DTT 23.62 (+) PLP, (−) DTT 33.21 (−) PLP, (+) DTT 40.08 (+) PLP, (+) DTT 54.65 - The cysteine conversion rates of Ape-OPSS and Msm-T according to temperatures were examined. The enzymatic activity at 37° C. and 60° C. was measured 2, 5, 10, 30, and 60 min after reaction. The reaction was conducted under the condition of 100 mM HEPES (pH 7.4), 5 mM OPS, 10 mM Na2S, 0.2 mM PLP, and
CysM 50 μg/mL. The amount of produced cysteine was determined using the Gaitonde method. In the condition of a buffer, as shown inFIG. 2 , Ape-OPSS showed a faster initial reaction rate at 37° C. as well as higher reactivity at 60° C. than did Msm-T. - Ape-OPSS and Msm-T were analyzed for heat stability. Each of the enzymes was diluted to a concentration of 2 mg/mL in an OPS broth and thermally treated at 37° C. and 60° C. for 10, 30, 60, 120, and 240 min, followed by reaction at 37° C. for 30 min under the condition of 5 mM OPS, 10 mM Na2S, 0.2 mM PLP, and 100 mM HEPES (pH 7.4). For this reaction, 10 μg/mL Ape-OPSS and 50 μg/mL Msm-T were employed. The amounts of the produced cysteine were measured using the Gaitonde method. Ape-OPSS was observed to retain its intact activity in spite of heat treatment at 60° C. for 4 hours while the activity of Msm-T was maintained at 37° C., but decreased by 50% upon heat treatment at 60° C. for 30 min. The results are given in Table 12, below.
-
TABLE 12 Relative activity (%) Heating time (min) (—) 10 min 30 min 60 min 120 min 240 min Ape- OPSS 100 102 107 100 107 101 Msm- T 100 82 50 32 19 8 - An examination was made of the retention of enzymatic activity at 37° C. when Msm-T was used in an amount of 50 μg/mL, which is a practical concentration in OPS broth. In the absence of Na2S, 50 μg/mL Msm-T was treated, together with 50 mM OPS broth and 0.2 mM PLP, at 37° C. for 0.5, 1, 2, 4, and 6 hours, after which Na2S was added to induce the enzymatic reaction. After the reaction for 30 min, the activity of Msm-T was measured. The amounts of the produced cysteine were determined using the Gaitonde method. As a result, the activity of Msm-T was decreased below 50% 2 hours after reaction at 37° C. in OPS broth (Table 13).
-
TABLE 13 Time 0 30 min 60 min 120 min 240 min 360 min Cysteine 100 88 73 47 11 3 conversion rate (%) - The cysteine conversion rates of Ape-OPSS and Msm-T according to pH were measured. In 100 mM buffer, Ape-OPSS and Msm-T, each having a concentration of 50 μg/mL, were subjected to reaction at 37° C. for 10 min. In this regard, K-phosphate buffer with a pH of 6.4/7.0/7.4/8.0, Tris-HCl buffer with a pH of 7.0/7.4/8.0/8.5/8.8, and Na-carbonate buffer with a pH of 8.0/8.5/9.0/10.0 were used. The quantitative analysis of the produced cysteine was conducted using the Gaitonde method. As seen in
FIG. 3 , Msm-T exhibited the highest activity at a pH of from 8.0 to 9.0 irrespective of buffer. As for Ape-OPSS, its highest activity was detected in K-phosphate (pH 7.4), with an optimal pH differing from one buffer to another. - Effects of ions on the activity of the OPSS enzymes were examined as follows. In a reaction mixture containing 5 mM OPS, 10 mM Na2S, 0.2 mM PLP, and 100 mM HEPES (pH 7.4), the enzymes were subjected to reaction at 37° C. for 30 min in the presence of (NH4)2SO4 (1, 3, 5, 10, 20 g/L), KH2PO4 (0.5, 1, 2, 4, 8 g/L), or NH4Cl (0.2, 0.5, 1, 2 g/L). Ape-OPSS and Msm-T were used at a concentration of 10 μg/mL and 50 μg/mL, respectively. The amounts of the produced cysteine were determined using the Gaitonde method.
- No changes were detected in the cysteine conversion rate when (NH4)2SO4 or KH2PO4 was added to the reaction mixture. On the other hand, as seen in Table 14, the cysteine conversion rate was decreased with an increase in NH4Cl concentration. Particularly, the maximal enzyme activity was decreased by more than 70% when 2 g/L NH4Cl was added. Therefore, NH4Cl was observed to have a negative effect on the conversion activity of OPS sulfhydrylase.
-
TABLE 14 Relative activity (%) NH4Cl Ape-OPSS Msm- T 0 100.00 100.00 0.2 86.26 91.49 0.5 73.35 91.30 1 49.11 67.11 2 27.72 47.12 - An experiment was conducted to examine the effect of sulfur sources on the cysteine synthesis activity of each enzyme. In a reaction mixture containing 5 mM OPS, 0.2 mM PLP, and 100 mM HEPES, each enzyme (50 μg/mL Ape-OPSS, 50 μg/mL Msm-T) was subjected to reaction at 37° C. for 1 hour in the presence of 10 mM Na2S, NaSH, or Na2S2O3. The amounts of the produced cysteine were measured using the Gaitonde method. Ape-OPSS was observed to prefer Na2S2O3 as a sulfur source, whereas Msm-T prefers Na2S. The results are summarized in Table 15, below.
-
TABLE 15 Relative activity (%) Enzyme Na2S NaSH Na2S2O3 Ape-OPSS 100.0 95.2 142.3 Msm-T 106.7 98.3 66.2 - PCR was performed using primers of SEQ ID NOS: 35 and 36, with the pET28a-Msm-T vector serving as a template. The PCR product thus obtained was treated with EcoRV and HindIII and cloned into pCL-P(CJ1) to construct a recombinant vector named pCL-P(CJ1)-Msm-T. To examine a difference in the expression level of Msm-T between the pET system and the pCL-Pcj1 system, strains for expressing the enzyme were prepared. The pET system was introduced into Rosetta (DE3) while the pCL-Pcj1 system used the K12G strain. Single colonies taken from LB plates were inoculated into 5 mL of LB broth and cultured at 37° C. for 16 hours while shaking at 200 rpm. These cultures were transferred to 25 mL of fresh LB broth containing kanamycine or spectinomycine and 0.2% glucose (in 250 mL flasks) and incubated to an OD600 of 0.5-0.6, immediately after which 1 mM IPTG was added to the media to induce the enzymes to be expressed. During incubation at 37° C. while shaking at 200 rpm, the expression levels of the enzyme were measured at various culture times (8, 16, 24 hours). The enzyme expression levels of the two systems were analyzed on 14% SDS PAGE (
FIG. 4 ). - The conversion rates from purified OPS to cysteine of Msm-T and Ape-OPSS were determined. In the presence of 75 μg/mL of each of the enzymes and 0.2 mM PLP, 60 mM OPS purified from OPS fermentation broth was reacted with 120 mM Na2S at 37° C. or 70° C. for 30, 60, 90, and 120 min. The reaction was conducted only at 37° C. for Msm-T, but at both 37° C. and 70° C. for Ape-OPSS. The amounts of the produced cysteine were measured using the Gaitonde method. As seen in
FIG. 5 , a purified OPS fermentation broth served well as a substrate for the enzymatic conversion into cysteine. Particularly, the conversion rate of Ape-OPSS was increased at 70° C. even upon the use of the purified OPS fermentation broth. - When an OPS fermentation broth was used as a substrate, the cysteine conversion rates of Msm-T and Ape-OPSS were measured according to the concentrations of the enzymes. In the presence of 100 mM Na2S and 0.2 mM PLP, 50 mM of OPS fermentation broth was reacted with 5 μg/mL or 50 μg/mL of each of Msm-T and Ape-OPSS at 37° C. The amounts of the produced cysteine were measured using the Gaitonde method. As seen in
FIG. 6 , the highest conversion rate was detected in 50 μg/mL Msm-T. In addition, upon the use of OPS fermentation broth as a substrate, the activity of Msm-T was higher than that of Ape-OPSS. - To examine the effect of OPS concentration on the conversion rate of Msm-T, predetermined amounts of purified OPS were added to OPS fermentation broth to induce the conversion reaction. The enzyme was used in an amount of 50 μg. The amounts of cysteine in the reaction solution were measured using the Gaitonde method. Msm-T exhibited a version rate of as high as 100% when the concentration of OPS was about 30 g/L.
- When the concentration of OPS exceeded 50 g/L, both the conversion rate and the conversion percentage were found to decrease. From these results, it is understood that when OPS fermentation broth is used as a substrate, there is an optimal concentration ratio between OPS and the enzyme.
-
TABLE 16 Cysteine Conversion Rate (Msm- T 50 ug)Time 0 min 10 min 30 min 60 min 120 min 180 min OPS measured 0 23.03 65.38 65.70 61.95 55.35 10.65 g/l OPS measured 0 1.15 10.23 28.07 97.84 100.34 36.09 g/l OPS measured 0 0 2.36 7.41 42.69 66.67 55.6 g/l
Claims (15)
1. A method for producing cysteine or a derivative thereof, comprising:
1) culturing a recombinant microorganism in which the activity of endogeneous phosphoserine phosphatase (SerB) is reduced, to produce O-phosphoserine (OPS); and
2) reacting the OPS of step 1) with a sulfide in presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism expressing OPSS, to produce cysteine or a derivative thereof.
2. The method of claim 1 , wherein the phosphoserine phosphatase has an amino acid sequence of SEQ ID NO: 1 or 2.
3. The method of claim 1 , wherein the level of enzyme activity is reduced by using a technique selected from the group consisting of deletion of the chromosomal serB, the introduction of mutation into the chromosomal serB to reduce endogenouse SerB activity, the substitution of the chromosomal serB with a gene mutated to reduce the endogenouse SerB activity, the introduction of mutation into a regulatory region for the serB to reduce endogenouse SerB activity, and the introduction of an antisense oligonucleotide complementary to a transcript of the serB to inhibit the translation of the mRNA.
4. The method of claim 3 , wherein the recombinant microorganism in which the activity of endogenous SerB is disrupted is cultured in a medium containing glycine or serine.
5. The method of claim 4 , wherein the medium contains glycine in an amount of from 0.1 to 10 g/L.
6. The method of claim 4 , wherein the medium contains serine in an amount of from 0.1 to 5 g/L.
7. The method of claim 1 , wherein the recombinant microorganism is Escherichia sp. or Coryneform bacteria.
8. The method of claim 1 , wherein the sulfide of step 2) is selected from the group consisting of Na2S, NaSH, (NH4)2S, H2S, Na2S2O3 and a combination thereof.
9. The method of claim 1 , wherein the sulfide of step 2) is used at a molar concentration 0.1 to 3 times as high as that of OPS used in the enzymatic conversion.
10. The method of claim 1 , wherein the OPSS of step 2) is derived from at least one species selected from the group consisting of Aeropyrum pernix, Mycobacterium tuberculosis, Mycobacterium smegmatis and Trichomonas vaginalis.
11. The method of claim 10 , wherein the OPSS is a further modified to increase a conversion rate of step 2).
12. The method of claim 1 , wherein the conversion of step 2) is carried out in presence of a cofactor selected from 0.001˜2 mM PLP (pyridoxal-5-phosphate), 0.001˜100 mM DTT (dithiothreitol), and a combination thereof.
13. The method of claim 1 , further comprising isolating and purifying the cysteine or its derivatives.
14. A recombinant microorganism in which the activity of endogenous SerB is reduced.
15. The recombinant microorganism of claim 14 , deposited under accession No. KCCM11212P.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/276,661 US20170073715A1 (en) | 2010-10-20 | 2016-09-26 | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0102664 | 2010-10-20 | ||
KR20100102664 | 2010-10-20 | ||
KR1020110086081A KR101381048B1 (en) | 2010-10-20 | 2011-08-26 | A microorganism producing O-phosphoserine and the method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
KR10-2011-0086081 | 2011-08-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/276,661 Continuation US20170073715A1 (en) | 2010-10-20 | 2016-09-26 | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120190081A1 true US20120190081A1 (en) | 2012-07-26 |
Family
ID=46140801
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/278,105 Active US8557549B2 (en) | 2010-10-20 | 2011-10-20 | Microorganism producing O-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
US13/278,106 Active 2031-10-31 US9689009B2 (en) | 2010-10-20 | 2011-10-20 | Microorganism producing o-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
US13/278,102 Abandoned US20120190081A1 (en) | 2010-10-20 | 2011-10-20 | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same |
US15/276,661 Abandoned US20170073715A1 (en) | 2010-10-20 | 2016-09-26 | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/278,105 Active US8557549B2 (en) | 2010-10-20 | 2011-10-20 | Microorganism producing O-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
US13/278,106 Active 2031-10-31 US9689009B2 (en) | 2010-10-20 | 2011-10-20 | Microorganism producing o-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/276,661 Abandoned US20170073715A1 (en) | 2010-10-20 | 2016-09-26 | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same |
Country Status (12)
Country | Link |
---|---|
US (4) | US8557549B2 (en) |
JP (1) | JP5805202B2 (en) |
KR (1) | KR101381048B1 (en) |
CN (2) | CN102906272B (en) |
AU (1) | AU2011318810B2 (en) |
BR (1) | BR112013009746A8 (en) |
DK (1) | DK2444481T3 (en) |
ES (1) | ES2711830T3 (en) |
LT (1) | LT2444481T (en) |
MX (1) | MX343756B (en) |
MY (1) | MY159614A (en) |
RU (1) | RU2536250C1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014182119A1 (en) | 2013-05-10 | 2014-11-13 | Cj Cheiljedang Corporation | Novel rhtb protein variants and the method of producing o-phosphoserine using the same |
EP2994526A4 (en) * | 2013-05-10 | 2016-11-09 | Cj Cheiljedang Corp | Novel o-phosphoserine export protein and the method of producing o-phosphoserine using the same |
WO2018124778A1 (en) | 2016-12-29 | 2018-07-05 | 씨제이제일제당 (주) | Escherichia sp. microorganism producing o-phosphoserine and method for producing o-phosphoserine or l-cysteine using same |
US10323262B2 (en) | 2014-08-12 | 2019-06-18 | Cj Cheiljedang Corporation | Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same |
US10696990B2 (en) | 2015-09-11 | 2020-06-30 | Cj Cheiljedang Corporation | Variant of O-phosphoserine exporter and method of producing O-phosphoserine, cysteine, and its derivatives using the same |
WO2020226341A1 (en) | 2019-05-09 | 2020-11-12 | 씨제이제일제당 (주) | Microorganism producing l-amino acid and method for producing l-amino acid by using same |
WO2022055192A1 (en) | 2020-09-09 | 2022-03-17 | 씨제이제일제당 (주) | Novel o-phosphoserine export protein and methods for producing o-phosphoserine, cysteine, and cysteine derivative using same |
WO2022255839A1 (en) | 2021-06-03 | 2022-12-08 | 씨제이제일제당 (주) | Novel yhhs variant and method for producing o-phosphoserine, cysteine, and derivate of cysteine using same |
WO2022260215A1 (en) | 2021-06-11 | 2022-12-15 | 씨제이제일제당 (주) | Novel mdth variant and method for producing o-phosphoserine, cysteine, and derivate of cysteine using same |
WO2022270857A1 (en) | 2021-06-23 | 2022-12-29 | 씨제이제일제당 (주) | Recombinant microorganism in which expression of nadh:quinone oxidoreductase is controlled, and method for producing o-phosphoserine, cysteine, and derivative thereof by using same |
WO2023128568A1 (en) | 2021-12-31 | 2023-07-06 | 씨제이제일제당 (주) | O-phosphoserine-producing microorganism, and method for producing o-phosphoserine or l-cysteine by using same |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2744987C (en) | 2008-12-02 | 2018-01-16 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
SG10201700554VA (en) | 2011-07-19 | 2017-03-30 | Wave Life Sciences Pte Ltd | Methods for the synthesis of functionalized nucleic acids |
KR101404376B1 (en) | 2011-12-15 | 2014-06-11 | 씨제이제일제당 (주) | Method of producing cysteine or derivatives thereof using novel O-phosphoserine sulfhydrylase |
SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
BR112015000723A2 (en) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | chiral nucleic acid adjuvant |
WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
JPWO2015108046A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action |
MX2016009290A (en) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Chiral design. |
WO2016013844A1 (en) | 2014-07-21 | 2016-01-28 | 한국생명공학연구원 | Production method of phenylacetyl homoserine lactone derivative |
KR101735935B1 (en) | 2015-07-20 | 2017-05-16 | 씨제이제일제당 (주) | Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them |
KR101756338B1 (en) * | 2016-01-15 | 2017-07-10 | 고려대학교 산학협력단 | Variant Microorganism for Producing L-Cystein and Method for Preparing L-Cystein Using thereof |
US20200255874A1 (en) * | 2016-09-21 | 2020-08-13 | KOHJIN Life Sciences Co., Ltd. | Method for producing l-cysteine |
CN106591209A (en) * | 2016-12-29 | 2017-04-26 | 廊坊梅花生物技术开发有限公司 | Recombinant strain and preparation method thereof and method for producing L-threonine |
KR102025867B1 (en) * | 2017-07-13 | 2019-09-27 | 씨제이제일제당 주식회사 | A method for recovering and recycling phosphoric acid from a fermentation liquor or a fermentation waste liquor |
KR20190092951A (en) | 2018-01-31 | 2019-08-08 | 씨제이제일제당 (주) | Method for Preparing Natural L-cysteine Crystals by Continuous Chromatography |
KR20190092950A (en) | 2018-01-31 | 2019-08-08 | 씨제이제일제당 (주) | Method for Preparing Natural L-cysteine Hydrochloride Hydrate Crystals by Continuous Chromatography |
US20220064681A1 (en) * | 2018-12-26 | 2022-03-03 | Daesang Corporation | E. coli variant strain or corynebacterium glutamicum variant strain producing l-amino acids, and method for producing l-amino acids using same |
WO2021251734A1 (en) | 2020-06-09 | 2021-12-16 | 씨제이제일제당 (주) | O-phosphoserine export protein variant and method for producing o-phosphoserine, cysteine, and derivative thereof by using same |
CN114381417B (en) * | 2022-03-24 | 2022-06-24 | 中国科学院天津工业生物技术研究所 | Method for improving tolerance of corynebacterium glutamicum to inhibitor |
CN116926102A (en) * | 2023-07-19 | 2023-10-24 | 天津大学 | Method for producing 5-ALA by inhibiting expression of global transcription regulatory factor gene glxR in corynebacterium glutamicum |
CN117551799B (en) * | 2024-01-11 | 2024-03-19 | 广东海洋大学 | Primer combination for nocardia seriolae strain typing, multiplex PCR identification method and application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083952B2 (en) * | 2000-03-01 | 2006-08-01 | Forschungszentrum Jülich GmbH | Nucleotide sequences coding for proteins involved in the biosynthesis of L-serine, an improved method for the microbial production of L-serine and a genetically modified microorganism suitable therefor |
US20070092957A1 (en) * | 2005-10-26 | 2007-04-26 | Donaldson Gail K | Fermentive production of four carbon alcohols |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19726083A1 (en) | 1997-06-19 | 1998-12-24 | Consortium Elektrochem Ind | Microorganisms and processes for the fermentative production of L-cysteine, L-cystine, N-acetyl-serine or thiazolidine derivatives |
JP3997631B2 (en) * | 1998-01-12 | 2007-10-24 | 味の素株式会社 | Method for producing L-serine by fermentation |
US6395528B1 (en) * | 2000-01-27 | 2002-05-28 | Ajinomoto Co., Inc. | Phosphoserine phosphatase gene of coryneform bacteria |
US6579705B2 (en) | 2001-04-04 | 2003-06-17 | Consortium Fur Elektrochemische Industrie Gmbh | Process for preparing non-proteinogenic L-amino acids |
RU2275425C2 (en) * | 2003-11-03 | 2006-04-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | Bacterium belonging to genus escherichia as producer of l-cysteine and method for preparing l-cysteine |
DE102004035052A1 (en) * | 2004-07-20 | 2006-02-16 | Basf Ag | Microorganisms for the production of sulfur-containing compounds |
KR100620092B1 (en) | 2004-12-16 | 2006-09-08 | 씨제이 주식회사 | Novel promoter nucleic acid derived from corynebacterium genus bacteria expression cassette comprising the promoter and vector comprising the cassette host cell comprising the vector and method for expressing a gene using the cell |
WO2006082254A2 (en) * | 2005-02-07 | 2006-08-10 | Metabolic Explorer | Microorganisms comprising enzymes expressed with low gamma-elimination activity |
JP2006304673A (en) * | 2005-04-28 | 2006-11-09 | National Institute Of Advanced Industrial & Technology | Method for enhancing substrate specificity of cysteine synthase for phosphoserine |
AU2006261356A1 (en) * | 2005-06-17 | 2006-12-28 | Microbia, Inc. | Improved amino acid and metabolite biosynthesis |
KR100905381B1 (en) * | 2006-07-28 | 2009-06-30 | 씨제이제일제당 (주) | Microorganism producing l-methionine precursor and method of producing l-methionine and organic acid from the l-methionine precurosr |
-
2011
- 2011-08-26 KR KR1020110086081A patent/KR101381048B1/en active IP Right Grant
- 2011-10-18 MY MYPI2013001406A patent/MY159614A/en unknown
- 2011-10-18 CN CN201180002042.3A patent/CN102906272B/en active Active
- 2011-10-18 JP JP2013534806A patent/JP5805202B2/en active Active
- 2011-10-18 CN CN201510065315.9A patent/CN104862352B/en active Active
- 2011-10-18 AU AU2011318810A patent/AU2011318810B2/en active Active
- 2011-10-18 BR BR112013009746A patent/BR112013009746A8/en not_active Application Discontinuation
- 2011-10-18 RU RU2013122805/10A patent/RU2536250C1/en active
- 2011-10-18 MX MX2013004495A patent/MX343756B/en active IP Right Grant
- 2011-10-19 ES ES11185852T patent/ES2711830T3/en active Active
- 2011-10-19 DK DK11185852.8T patent/DK2444481T3/en active
- 2011-10-19 LT LTEP11185852.8T patent/LT2444481T/en unknown
- 2011-10-20 US US13/278,105 patent/US8557549B2/en active Active
- 2011-10-20 US US13/278,106 patent/US9689009B2/en active Active
- 2011-10-20 US US13/278,102 patent/US20120190081A1/en not_active Abandoned
-
2016
- 2016-09-26 US US15/276,661 patent/US20170073715A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083952B2 (en) * | 2000-03-01 | 2006-08-01 | Forschungszentrum Jülich GmbH | Nucleotide sequences coding for proteins involved in the biosynthesis of L-serine, an improved method for the microbial production of L-serine and a genetically modified microorganism suitable therefor |
US20070092957A1 (en) * | 2005-10-26 | 2007-04-26 | Donaldson Gail K | Fermentive production of four carbon alcohols |
Non-Patent Citations (11)
Title |
---|
Agren et al., Journal of Biological Chemistry 283(46):31567-31574, 2008 * |
Branch, A., TIBS 23:45-50, 1998 * |
Branden et al., Introduction to Protein Structure, Garland Publishing Inc., New York, page 247, 1991 * |
Fleischmann et al., Genbank accession number ABK70074, March 2010 * |
GenBank accession number Q9YBL2, 2/7/2006 * |
GenBank accession number WP_003406912, 6/22/2013 * |
Ravnikar et al., Journal of Bacteriology 169(6):2611-2617, 1987 * |
Ryu et al., Process Biochemistry 32(3):201-209, 1997 * |
Seffernick et al., J. Bacteriol. 183(8):2405-2410, 2001 * |
Sousa et al., Microbiology 148(Pt5):1291-1303, 2002 * |
Witkowski et al., Biochemistry 38:11643-11650, 1999 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10738091B2 (en) | 2013-05-10 | 2020-08-11 | Cj Cheiljedang Corporation | RHTB protein variants and the method of producing O-phosphoserine using the same |
US10752659B2 (en) | 2013-05-10 | 2020-08-25 | Cj Cheiljedang Corporation | RHTB protein variants and the method of producing O-phosphoserine using the same |
US9765124B2 (en) | 2013-05-10 | 2017-09-19 | Cj Cheiljedang Corporation | RhtB protein variants and the method of producing O-phosphoserine using the same |
US10344059B2 (en) | 2013-05-10 | 2019-07-09 | Cj Cheiljedang Corporation | RhtB protein variants and the method of producing O-phosphoserine using the same |
US10041098B2 (en) | 2013-05-10 | 2018-08-07 | Cj Cheiljedang Corporation | O-phosphoserine export protein and the method of producing O-phosphoserine using the same |
US10125179B2 (en) | 2013-05-10 | 2018-11-13 | Cj Cheiljedang Corporation | RhtB protein variants and the method of producing O-phosphoserine using the same |
TWI648290B (en) * | 2013-05-10 | 2019-01-21 | Cj第一製糖股份有限公司 | Novel RhtB protein variant and method for producing O-phosphoric acid using the same |
WO2014182119A1 (en) | 2013-05-10 | 2014-11-13 | Cj Cheiljedang Corporation | Novel rhtb protein variants and the method of producing o-phosphoserine using the same |
EP2994526A4 (en) * | 2013-05-10 | 2016-11-09 | Cj Cheiljedang Corp | Novel o-phosphoserine export protein and the method of producing o-phosphoserine using the same |
US10323262B2 (en) | 2014-08-12 | 2019-06-18 | Cj Cheiljedang Corporation | Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same |
US10696990B2 (en) | 2015-09-11 | 2020-06-30 | Cj Cheiljedang Corporation | Variant of O-phosphoserine exporter and method of producing O-phosphoserine, cysteine, and its derivatives using the same |
EP3564359A4 (en) * | 2016-12-29 | 2020-11-18 | CJ Cheiljedang Corporation | Escherichia |
US10947495B2 (en) | 2016-12-29 | 2021-03-16 | Cj Cheiljedang Corporation | Microorganism of the genus Escherichia producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same |
WO2018124778A1 (en) | 2016-12-29 | 2018-07-05 | 씨제이제일제당 (주) | Escherichia sp. microorganism producing o-phosphoserine and method for producing o-phosphoserine or l-cysteine using same |
WO2020226341A1 (en) | 2019-05-09 | 2020-11-12 | 씨제이제일제당 (주) | Microorganism producing l-amino acid and method for producing l-amino acid by using same |
WO2022055192A1 (en) | 2020-09-09 | 2022-03-17 | 씨제이제일제당 (주) | Novel o-phosphoserine export protein and methods for producing o-phosphoserine, cysteine, and cysteine derivative using same |
WO2022255839A1 (en) | 2021-06-03 | 2022-12-08 | 씨제이제일제당 (주) | Novel yhhs variant and method for producing o-phosphoserine, cysteine, and derivate of cysteine using same |
WO2022260215A1 (en) | 2021-06-11 | 2022-12-15 | 씨제이제일제당 (주) | Novel mdth variant and method for producing o-phosphoserine, cysteine, and derivate of cysteine using same |
WO2022270857A1 (en) | 2021-06-23 | 2022-12-29 | 씨제이제일제당 (주) | Recombinant microorganism in which expression of nadh:quinone oxidoreductase is controlled, and method for producing o-phosphoserine, cysteine, and derivative thereof by using same |
WO2023128568A1 (en) | 2021-12-31 | 2023-07-06 | 씨제이제일제당 (주) | O-phosphoserine-producing microorganism, and method for producing o-phosphoserine or l-cysteine by using same |
Also Published As
Publication number | Publication date |
---|---|
AU2011318810B2 (en) | 2015-09-24 |
RU2013122805A (en) | 2014-11-27 |
US8557549B2 (en) | 2013-10-15 |
CN102906272A (en) | 2013-01-30 |
KR20120041115A (en) | 2012-04-30 |
US20170073715A1 (en) | 2017-03-16 |
JP5805202B2 (en) | 2015-11-04 |
MX343756B (en) | 2016-11-18 |
CN102906272B (en) | 2016-07-06 |
ES2711830T3 (en) | 2019-05-07 |
BR112013009746A8 (en) | 2018-07-03 |
US9689009B2 (en) | 2017-06-27 |
US20120190083A1 (en) | 2012-07-26 |
BR112013009746A2 (en) | 2016-11-22 |
CN104862352A (en) | 2015-08-26 |
AU2011318810A1 (en) | 2013-05-02 |
US20120190082A1 (en) | 2012-07-26 |
RU2536250C1 (en) | 2014-12-20 |
JP2013543723A (en) | 2013-12-09 |
CN104862352B (en) | 2021-10-26 |
KR101381048B1 (en) | 2014-04-14 |
LT2444481T (en) | 2019-02-25 |
DK2444481T3 (en) | 2019-03-25 |
MX2013004495A (en) | 2014-04-14 |
MY159614A (en) | 2017-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170073715A1 (en) | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same | |
EP2444481B1 (en) | Microorganism producing O-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same | |
JP5371073B2 (en) | L-methionine precursor producing strain | |
RU2346038C2 (en) | Fermentative method of producing amino acids and amino acid derivatives from phosphoglycerate family | |
US9127324B2 (en) | O-phosphoserine sulfhydrylase mutants and method for production of cysteine using the same | |
JP2008529485A (en) | Microorganisms containing expressed enzymes with low γ-eliminating activity | |
US10752659B2 (en) | RHTB protein variants and the method of producing O-phosphoserine using the same | |
US9243268B2 (en) | Method for preparing cysteine or a derivative thereof using a novel O-phosphoserine sulfhydrylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CJ CHEILJEDANG CORPORATION, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANG, JIN SOOK;JO, JAE HYUN;BAE, HYUN AE;AND OTHERS;REEL/FRAME:028015/0079 Effective date: 20120329 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |